<DOC>
	<DOC>NCT02116803</DOC>
	<brief_summary>The study allows continued safety follow-up of patients who are on single agent dovitinib or dovitinib in combination with fulvestrant treatment in a Novartis-sponsored study which has met its primary endpoint and are benefiting from the treatment as judged by the investigator.</brief_summary>
	<brief_title>An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective</brief_title>
	<detailed_description />
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>patient is currently enrolled in Novartis sponsored study, which has met its endpoint and is receiving single agent oral dovitinib or dovitinib and fulvestrant coadministration patient is currently benefiting from treatment with single agent oral dovitinib or dovitinib and fulvestrant coadministration as determined by the guidelines of the parent protocol and according to the investigator's clinical judgment. patient has demonstated compliance patient has given written informed consent. patient has been permanently discontinued from oral dovitinib study treatment, either alone or in combination with fulvestrant, in the parent study patient is pregnant or nursing at the time of entry women of childbearing potential and male patients with sexual partners of childbearing potential unwilling to use highly effective methods of contraception during dosing and for a specified duration after stopping study treatment Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>solid tumors,</keyword>
	<keyword>TKI258</keyword>
</DOC>